Table 1 Baseline demographics at time of treatment access request for the total population who received ≥ 1 lanadelumab dose
From: Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
Patient characteristic | n = 77 |
|---|---|
Median (range) age, y | 42.4 (11.7–78.9) |
Age, y, n (%) | |
< 18 | 6 (7.8) |
18–64 | 63 (81.8) |
≥ 65 | 8 (10.4) |
Female, n (%) | 53 (68.8) |
Weight (kg) | |
Mean (SD) | 75.8 (20.6) |
Age at diagnosis, years | |
Median (range) | 10.0 (1–48) |
HAE type | |
1 | 68 (88.3) |
2 | 7 (9.1) |
HAE nC1-INHa | 1 (1.3) |
Acquired angioedema | 1 (1.3) |
Positive family history of HAE, n (%) | 52 (67.5%) |
Proportion of laryngeal attacks for the 3 most severe attacks in the 6 months prior to ATU entry, n (%) | |
Number of severe attacks | 149 |
Proportion of pharyngo-laryngeal attacks | 12 (8.1) |
Number of HAE attacks in the 6 months prior to ATU entry, median (range) (n = 70) | 13.5 (1–99) |
Exposure to LTP prior to ATU entry, n (%)b | 72 (93.5) |
Ongoing LTP prior to ATU entry, n (%) | 60 (77.9) |
Single oral agentc | 20 (26.0) |
Single C1-INH agentd | 23 (29.9) |
Combination of LTP agents | 17 (22.1) |
Monthly attack rate 6 months prior to ATU entry for patients with ongoing LTP, mean (SD) | n = 52 2.53 (2.67) |
Number of attacks in the 6 months prior to ATU entry by ongoing LTP mean (SD) | |
No LTP | n = 13 20.0 (8.8) |
Single oral LTPs | n = 18 12.9 (8.7) |
Single C1-INH LTPs | n = 17 17.4 (13.3) |
LTP combinations | n = 17 15.4 (23.4) |